Brookline Capital Management Initiates Coverage on Palisade Bio (NASDAQ:PALI)

Stock analysts at Brookline Capital Management began coverage on shares of Palisade Bio (NASDAQ:PALI) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage set a “buy” rating and a $38.00 price target on the stock.

Separately, Maxim Group cut their price target on shares of Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Palisade Bio Stock Performance

NASDAQ:PALI traded up $0.01 during mid-day trading on Wednesday, hitting $2.44. The stock had a trading volume of 256,093 shares, compared to its average volume of 402,988. Palisade Bio has a twelve month low of $2.18 and a twelve month high of $22.35. The stock has a market cap of $3.24 million, a price-to-earnings ratio of -0.18 and a beta of 1.36. The company’s 50 day simple moving average is $3.28 and its 200 day simple moving average is $4.07.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter, beating the consensus estimate of ($3.35) by $1.03. As a group, equities analysts forecast that Palisade Bio will post -13.11 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.